Today on Drug Discovery & Development
FDA greenlights ViiV’s Tivicay PD for HIV-positive newborns in first month of life
The FDA has approved ViiV Healthcare’s Tivicay PD (dolutegravir) for treating HIV-1 in pediatric patients weighing at least 2 kg, including eligible newborns, the company and FDA announced. FDA first approved Tivicay in August 2013 for adults and adolescents aged 12 or older weighing at least 40 kg (about 88.2 pounds). The agency approved the…
FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide
In April, The New York Times proclaimed that a gen-AI-driven company that hawked compounded GLP-1 drugs was potentially on track to have $1.8 billion in 2026 sales. The paper also reported that the company, MEDVi, had generated $401 million in sales in 2025, saying it had been given access to unspecified company financials. By then,…
Drug Discovery and Development See More >
FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide
In April, The New York Times proclaimed that a gen-AI-driven company that hawked compounded GLP-1 drugs was potentially on track to have $1.8 billion in 2026 sales. The paper also reported that the company, MEDVi, had generated $401 million in sales in 2025, saying it had been given access to unspecified company financials. By then,…
As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%
Sai Life Sciences’ bet on information-dense scale-up and how it is responding to pharma clients who want acceleration
Ahead of PharmSci 360, DigiM CEO on turning hidden microstructures into drug-release predictions
CEO of CDMO AustinPx on its exclusive agreement with Thermo Fisher’s Patheon division
Sponsored Content See More >
Top Automated Dispensing Cabinets for Pharmacies: Leading Brands ComparedSimplifying workflows is essential. Individuals in the pharmacy industry may accomplish more work with fewer errors by automating medication distribution.…
How Endogenous Tagging is Reshaping Protein AnalysisUnderstanding how proteins behave inside living cells is essential for modern drug discovery. Yet many widely used approaches, particularly plasmid…
What sets oncology biosimilars apart: Anticipating key challenges in the development landscapeBy Kimberly Salgado, ICON plc Advancements in biologic therapies have greatly improved our ability to treat cancer over the last…
Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Designby Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process…
Complexity’s counterpoint: Understanding protocol optimization In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints…
Optimizing Data Pipelines in Life Sciences with AI-Driven Integration and FHIRSponsored by Infor. Data management in life sciences is inherently complex. Data is fragmented across multiple systems — such…
Accelerating life sciences with AI This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…
Advancing Clinical Trials and ResearchThis case study is sponsored by Infor. In the complex landscape of clinical trials and medical research, data fragmentation remains…
Multidisciplinary approaches optimize contract drug discovery
5 Key Questions in Conducting Global Usability StudiesBy Dr Bryce G Rutter, Head Noble Consulting Services Evaluating device usability throughout the product development process is crucial. A…
Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic HandsBy Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the…
Ask the Expert: Navigating the New FDA Rules on Laboratory Developed Tests (LDTs)The U.S. FDA released a final rule to regulate laboratory developed tests (LDTs) on May 6, 2024, making it clear…
Genomics/Proteomics See More >
New cell imaging method reveals hidden enzyme activity
Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the optical readout of…
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Infectious Disease See More >
FDA greenlights ViiV’s Tivicay PD for HIV-positive newborns in first month of life
The FDA has approved ViiV Healthcare’s Tivicay PD (dolutegravir) for treating HIV-1 in pediatric patients weighing at least 2 kg, including eligible newborns, the company and FDA announced. FDA first approved Tivicay in August 2013 for adults and adolescents aged 12 or older weighing at least 40 kg (about 88.2 pounds). The agency approved the…
Oncology See More >
As chemo overtreatment comes into focus, Atossa bets on tamoxifen’s active form
As evidence mounts that some hormone receptor-positive, HER2-negative breast cancer patients are being overtreated with chemotherapy, researchers are working to identify which patients can safely avoid it, and to expand the treatment options available to those who can. Atossa Therapeutics thinks endoxifen, the active metabolite behind tamoxifen, could be an important addition to that toolkit. …
How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
Calderasib’s real innovation: designed for combinability and potency
